Evidence map›Paper›PMID 32239646›Full record

ReviewESC heart failure2020

Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines.

Luca Branca, Marco Sbolli, Marco Metra, Marat Fudim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. ATScientific reports · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luca BrancaCardiothoracic Department, Civil Hospitals; Department of Medical and Surgical Specialities, Radioloogical Sciences, Public Health, University of Brescia, Brescia, Italy.
Marco SbolliCardiothoracic Department, Civil Hospitals; Department of Medical and Surgical Specialities, Radioloogical Sciences, Public Health, University of Brescia, Brescia, Italy.
Marco MetraCardiothoracic Department, Civil Hospitals; Department of Medical and Surgical Specialities, Radioloogical Sciences, Public Health, University of Brescia, Brescia, Italy.
Marat FudimDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.

Funding

American Heart Association 17MCPRP33460225
6 · The paper itself

Abstract

Currently, the assessment of left ventricular ejection fraction (LVEF) is the cornerstone of the classification of patients with heart failure (HF). The mid-range LVEF (HFmrEF) category was identified in an attempt to uncover specific characteristics of these patients. So far, the analysis of trials, registries, and observational studies have demonstrated that patients with mid-range LVEF belong to a patient cohort with generally intermediate clinical profile as compared with other groups but with a remarkable variety of intrinsic phenotypes. This is due to the limitations of LVEF as the sole criterion to categorize patients with HF and characterize their prognosis, above all when it is >40%. To better define the HFmrEF phenotype, it is reasonable to consider other parameters, such as LVEF changes over time, HF aetiology, co-morbidities, and other imaging parameters. A multiparametric evaluation may contextualize a patient with HFmrEF in a more defined phenotype with a specific prognosis.

Indexed as

CardiologyHeart FailureHumansPrognosisStroke VolumeVentricular Function, LeftClassificationHeart failure with mid-range ejection fractionHeart failure with preserved ejection fractionHeart failure with reduced ejection fraction

Identifiers

PMID32239646
PMCPMC7160484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.